Histone Demethylase JMJD2B Coordinates H3K4/H3K9 Methylation and Promotes Hormonally Responsive Breast Carcinogenesis

Total Page:16

File Type:pdf, Size:1020Kb

Histone Demethylase JMJD2B Coordinates H3K4/H3K9 Methylation and Promotes Hormonally Responsive Breast Carcinogenesis Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis Lei Shia,1, Luyang Suna,1, Qian Lia, Jing Lianga, Wenhua Yua, Xia Yia, Xiaohan Yanga, Yanyan Lia, Xiao Hana, Yu Zhanga, Chenghao Xuana, Zhi Yaob, and Yongfeng Shanga,b,2 aKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China; and bTianjin Medical University, Tianjin 300070, China Edited* by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved March 23, 2011 (received for review November 23, 2010) It is well-documented that the methylation of histone H3 lysine and Trithorax) domain. In mammalian cells, multiple HMTs 4 (H3K4) and of H3K9 are mutually exclusive, an epigenetic have been characterized: SET1A and SET1B (the mammalian phenomenon conserved from yeast to humans. How this op- orthologs of yeast Set1), five mixed-lineage leukemia (MLL)- posed methylation modification is accomplished and coordinated family HMTs (MLL1–5),SMYD3,andSET7/9(14).Thein- in mammalian cells is poorly understood. Here we report that the creased complexity of the enzymatic machineries suggests that H3K9 trimethyl demethylase JMJD2B is an integral component of H3K4 methylation is biologically important and subject to the H3K4-specific methyltransferase, the mixed-lineage leukemia sophisticated controls in higher eukaryotes. Indeed, many (MLL) 2 complex. We show that theJMJD2B/MLL2complexis H3K4 methyltransferases in mammalian cells are essential copurified with estrogen receptor α (ERα) and is required for genes (15–17). ERα-regulated transcription. We demonstrate that H3K9 deme- The demethylation state of H3K9 is believed to be maintained thylation and H3K4 methylation are coordinated in ERα-activated by several members of the JmjC domain family of demethylases. transcription such that H3K9 demethylation is a prerequisite for Specifically, it has been reported that, in euchromatin, JHDM2A H3K4 methylation. Significantly, depletion of JMJD2B impairs the catalyzes the removal of mono- and dimethylation at H3K9 estrogen-induced G1/S transition of the cell cycle in vitro and (H3K9me1/2) (18) and JMJD2C acts to erase trimethylation at inhibits breast tumorigenesis in vivo. Interestingly, JMJD2B itself H3K9 (H3K9me3) (19), whereas JMJD2B has been shown to is an ERα target gene, and forms a feed-forward regulatory loop demethylate H3K9me3 at pericentric heterochromatin in mam- in regulation of the hormone response. Our results provide a mo- malian cells (20, 21). A role for JMJD2B in euchromatin func- lecular basis for the coordinated H3K4 methylation/H3K9 deme- tion has not yet been defined. thylation in transcription activation, link the trimethyl demethylase Here we report that the H3K9 trimethyl demethylase JMJD2B JMJD2B to euchromatin functions, and provide a mechanism for is physically associated with and an integral component of the JMJD2B in breast carcinogenesis. H3K4 methyltransferase MLL2 complex. We demonstrate that the JMJD2B/MLL2 complex interacts with ERα and is required histone methylation | breast cancer for the cellular function of ERα. We show that JMJD2B and the MLL2 complex interact to define the methylation status of H3K4 α ecent studies indicate that, analogous to other covalent his- and H3K9 in ER -activated transcription, in which H3K9 de- fi tone modifications such as acetylation, histone methylation is methylation precedes H3K4 methylation. In addition, we nd R α reversible. However, in contrast to histone acetylation, which is that JMJD2B itself is transcriptionally targeted by ER and may generally associated with active transcription, histone methyla- thus form a feed-forward regulatory loop in promoting hor- tion can be associated with either activation or repression of monally responsive breast carcinogenesis. MEDICAL SCIENCES transcription, depending on what effector protein is recruited Results and Discussion (1). Even within the same lysine residue, the biological con- sequences of methylation seem to be variable. For example, JMJD2B Is Physically Associated with the MLL2 Complex. To further methylation of histone H3 lysine 9 (H3K9), long considered understand the biological activity of JMJD2B and to investigate a hallmark of heterochromatin (2–8), was recently found to also its role, if any, in euchromatin functions, we generated a mam- mary carcinoma MCF-7 cell line that stably expresses FLAG- be present at the transcribed regions of active mammalian genes fi (9, 10), suggesting that certain methyl marks can have multiple tagged JMJD2B (FLAG-JMJD2B). Immunopuri cation of functions in the cell. JMJD2B from MCF-7 cell extracts with anti-FLAG and analysis Given the complexity of histone methylation modification, the of the JMJD2B-containing protein complex by mass spectrom- integration and/or coordination of methylation/demethylation in etry revealed that JMJD2B is associated with multiple com- a particular biological process becomes an issue of great im- ponents of the MLL2 complex (MLL2, ASH2L, RbBP5, and portance in further understanding the role of histone methyla- tion in nucleosome functioning. Specifically, actively transcribed genes, including the ones that are regulated by estrogen receptor Author contributions: L. Shi, L. Sun, Q.L., J.L., W.Y., X. Yi, X. Yang, and Y.S. designed – research; L. Shi, L. Sun, Q.L., J.L., W.Y., X. Yi, X. Yang, Y.L., X.H., Y.Z., and C.X. performed (ER) (11 13), are marked by methylation at histone H3K4, but research; Z.Y. contributed new reagents/analytic tools; L. Shi, L. Sun, Q.L., J.L., W.Y., X. Yi, at the same time by demethylation at H3K9; H3K4 and H3K9 X. Yang, Y.L., X.H., Y.Z., C.X., Z.Y., and Y.S. analyzed data; and L. Shi, L. Sun, and Y.S. methylation levels are mutually exclusive, and this relationship is wrote the paper. conserved from fission yeast to humans. How opposed H3K4 The authors declare no conflict of interest. methylation and H3K9 demethylation are achieved and co- *This Direct Submission article had a prearranged editor. ordinated in transcription activation in mammalian cells is not 1L. Shi and L. Sun contributed equally to this work. fully understood. 2To whom correspondence should be addressed. E-mail: [email protected]. H3K4 methylation is deposited by a family of histone meth- This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. yltransferases (HMT) that share a conserved SET (Su(var), E(z), 1073/pnas.1017374108/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1017374108 PNAS | May 3, 2011 | vol. 108 | no. 18 | 7541–7546 Downloaded by guest on September 28, 2021 WDR5) as well as with several other proteins (hnRNP U, by coimmunoprecipitation experiments. Immunoprecipitation of HSP70, and ribosomal protein S9). Interestingly, four peptides MCF-7 cell extracts with antibodies against MLL2, WDR5, matching ERα were also identified in the JMJD2B-containing RbBP5, ASH2L, or JMJD2B followed by immunoblotting with protein complex (Fig. 1A and SI Appendix, Supplemental File 1). antibodies against ERα revealed that all components of the To confirm the in vivo association between JMJD2B and the JMJD2B/MLL2 complex including MLL2, but not MLL3, were MLL2 complex, coimmunoprecipitation experiments were per- coimmunoprecipitated with ERα (Fig. 2A Left). Reciprocally, formed with MCF-7 cell extracts. Immunoprecipitation with immunoprecipitation with antibodies against ERα followed by antibodies against JMJD2B followed by immunoblotting with immunoblotting with antibodies against MLL2, WDR5, RbBP5, antibodies against WDR5, RbBP5, ASH2L, or MLL2 demon- ASH2L, or JMJD2B demonstrated that ERα was associated with strated that JMJD2B was coimmunoprecipitated with all of these all of these proteins in vivo (Fig. 2A Right). components of the MLL2 complex, but not with JARID1B Next, we tested the effect of the JMJD2B/MLL2 complex on (PLU-1), another member of the JmjC domain-containing de- ERα-regulated transcription. To this end, MCF-7 cells were methylase, although JARID1B could be effectively immuno- transfected with specific siRNA molecules to knock down the precipitated with antibodies against HDAC1 (22) (Fig. 1B Left). expression of MLL2 or JMJD2B. The cells were deprived of Reciprocally, immunoprecipitation with antibodies against the estrogen for at least 3 d and treated with 17β-estradiol (E2). components of the MLL2 complex and immunoblotting with Real-time RT-PCR measurements revealed that knockdown of antibodies against JMJD2B also revealed that WDR5, RbBP5, either MLL2 or JMJD2B severely inhibited E2-stimulated ex- ASH2L, and MLL2, but not MLL1 and MLL4, were coimmu- pression of endogenous ERα target genes, including TFF1, noprecipitated with JMJD2B, although MLL1 and MLL4 could EBAG9, cathepsin D, and GREB1 (Fig. 2B), although to variable be efficiently coimmunoprecipitated with RbBP5, a subunit extents. The efficiency and specificity of MLL2 and JMJD2B shared by all of the MLL1–4 complexes (17, 23, 24) (Fig. 1B knockdown were examined by real-time quantitative RT-PCR Right). A weak interaction between JMJD2B and MLL3 was also and/or Western blotting analysis (Fig. 2C). These results indicate detected (Fig. 1B Lower Right). Collectively, these results sup- that the JMJD2B/MLL2 complex is required for ERα-activated port the suggestion that JMJD2B is physically associated with the gene transcription. MLL2 complex in vivo. To further support this
Recommended publications
  • Chromosomal Aberrations in Head and Neck Squamous Cell Carcinomas in Norwegian and Sudanese Populations by Array Comparative Genomic Hybridization
    825-843 12/9/08 15:31 Page 825 ONCOLOGY REPORTS 20: 825-843, 2008 825 Chromosomal aberrations in head and neck squamous cell carcinomas in Norwegian and Sudanese populations by array comparative genomic hybridization ERIC ROMAN1,2, LEONARDO A. MEZA-ZEPEDA3, STINE H. KRESSE3, OLA MYKLEBOST3,4, ENDRE N. VASSTRAND2 and SALAH O. IBRAHIM1,2 1Department of Biomedicine, Faculty of Medicine and Dentistry, University of Bergen, Jonas Lies vei 91; 2Department of Oral Sciences - Periodontology, Faculty of Medicine and Dentistry, University of Bergen, Årstadveien 17, 5009 Bergen; 3Department of Tumor Biology, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center, Montebello, 0310 Oslo; 4Department of Molecular Biosciences, University of Oslo, Blindernveien 31, 0371 Oslo, Norway Received January 30, 2008; Accepted April 29, 2008 DOI: 10.3892/or_00000080 Abstract. We used microarray-based comparative genomic logical parameters showed little correlation, suggesting an hybridization to explore genome-wide profiles of chromosomal occurrence of gains/losses regardless of ethnic differences and aberrations in 26 samples of head and neck cancers compared clinicopathological status between the patients from the two to their pair-wise normal controls. The samples were obtained countries. Our findings indicate the existence of common from Sudanese (n=11) and Norwegian (n=15) patients. The gene-specific amplifications/deletions in these tumors, findings were correlated with clinicopathological variables. regardless of the source of the samples or attributed We identified the amplification of 41 common chromosomal carcinogenic risk factors. regions (harboring 149 candidate genes) and the deletion of 22 (28 candidate genes). Predominant chromosomal alterations Introduction that were observed included high-level amplification at 1q21 (harboring the S100A gene family) and 11q22 (including Head and neck squamous cell carcinoma (HNSCC), including several MMP family members).
    [Show full text]
  • Associated Antigen 9 Exerts in Vivo Tumor- Promoting Effects Via Its Coiled-Coil Region
    INTERNATIONAL JOURNAL OF ONCOLOGY 39: 41-49, 2011 Intracellular estrogen receptor-binding fragment- associated antigen 9 exerts in vivo tumor- promoting effects via its coiled-coil region YOSHIHIRO MAEYAMA1,2, MAKOTO OTSU3, SHUJI KUBO4, TOMOKI YAMANO5, YASUAKI IIMURA1,2, MASAFUMI ONODERA6, SATOSHI KONDO2, YUKIO SAKIYAMA1 and TADASHI ARIGA1,7 1Group of Human Gene Therapy, 2Department of Surgical Oncology, Hokkaido University Graduate School of Medicine, N15W7 Sapporo, Hokkaido 060-8638; 3Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639; 4Department of Genetics and 5Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501; 6Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535; 7Department of Pediatrics, Hokkaido University Graduate School of Medicine, N15W7 Sapporo, Hokkaido 060-8638, Japan Received February 22, 2011; Accepted April 6, 2011 DOI: 10.3892/ijo.2011.1026 Abstract. Estrogen receptor-binding fragment-associated showed a predominantly cytoplasmic localization in the antigen 9 (EBAG9) is a tumor-promoting factor of largely tumor cells. Collectively, these results suggest that EBAG9 unknown function. To assess a causative role of EBAG9 in overexpression can be causative in enhancing the malignant advanced malignancies, we generated the EG7-OVA and properties of tumor cells, and that tumor promotion likely MethA murine tumor cell lines that stably express full-length requires EBAG9 intracellular association with as yet unidentified or truncated EBAG9 protein, using retroviral-mediated gene binding partners via the coiled-coil region.
    [Show full text]
  • Estrogen Receptor–Binding Fragment–Associated Antigen 9 Is a Tumor-Promoting and Prognostic Factor for Renal Cell Carcinoma
    Research Article Estrogen Receptor–Binding Fragment–Associated Antigen 9 Is a Tumor-Promoting and Prognostic Factor for Renal Cell Carcinoma Tetsuo Ogushi,1 Satoru Takahashi,1 Takumi Takeuchi,1 Tomohiko Urano,2 Kuniko Horie-Inoue,3 Jinpei Kumagai,1 Tadaichi Kitamura,1 Yasuyoshi Ouchi,2 Masami Muramatsu,3 and Satoshi Inoue2,3 Departments of 1Urology and 2Geriatric Medicine, Faculty of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan and 3Research Center for Genomic Medicine, Saitama Medical School, Yamane, Hidaka-shi, Saitama, Japan Abstract target organs as well as several other tissues such as brain, liver, The estrogen receptor–binding fragment–associated antigen and kidney (2). The protein expression of EBAG9 is estrogen inducible, as it has been shown in ovariectomized mice treated 9(EBAG9) has been identified as a primary estrogen- h responsive gene in human breast cancer MCF7 cells. A high with 17 -estradiol administration (2). The physiologic function of expression of EBAG9 has been observed in invasive breast EBAG9 has not been well defined, yet the molecule may be cancer and advanced prostate cancer, suggesting a tumor- implicated in cancer pathophysiology, with several lines of evidence promoting role of the protein in malignancies. Here we show of the protein expression in malignancies, including breast (3), that intratumoral (i.t.) administration of small interfering ovarian (4), prostate (5), and hepatocellular carcinomas (6). In RNA against EBAG9 exerted overt regression of tumors prostate cancer (5), EBAG9 expression significantly correlated with following s.c. implantation of murine renal cell carcinoma advanced pathologic stages and high Gleason score (P = 0.0305 and P < 0.0001, respectively), suggesting the abundance of EBAG9 may (RCC) Renca cells.
    [Show full text]
  • Anti-RCAS1 / Estrogen Receptor Binding Site Associated, Antigen 9 Monoclonal Antibody(Clone: CPTC-EBAG9-2)
    9853 Pacific Heights Blvd. Suite D. San Diego, CA 92121, USA Tel: 858-263-4982 Email: [email protected] 36-3485: Anti-RCAS1 / Estrogen Receptor Binding Site Associated, Antigen 9 Monoclonal Antibody(Clone: CPTC-EBAG9-2) Clonality : Monoclonal Clone Name : CPTC-EBAG9-2 Application : IHC Reactivity : Human Gene : EBAG9 Gene ID : 9166 Uniprot ID : O00559 BAG9; cancer associated surface antigen; cancer associated surface antigen RCAS1; EB9; Alternative Name : estrogen receptor binding fragment associated gene 9; PDAF; receptor binding cancer antigen expressed on SiSo cells Isotype : Mouse IgG2a, kappa Immunogen Information : Recombinant full-length human EBAG9 protein Description EBAG9, also known as RCAS1, is an estrogen-transcribed protein. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. RCAS1 is expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells, and acts as a ligand for a putative receptor present on peripheral lymphocytes. RCAS1 is highly expressed not only in cancer cells but also in non-tumor bile duct cells subject to immune attack. RCAS1 inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, contributing to the ability of tumor cells to evade host immune surveillance. High expression of RCAS1 significantly correlates with tumor progression and with poor outcome for many cancer patients. Product Info Amount : 20 µg / 100 µg 200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with Content : 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
    [Show full text]
  • EBAG9 / RCAS1 (28-213, His-Tag) Human Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AR09111PU-L EBAG9 / RCAS1 (28-213, His-tag) Human Protein Product data: Product Type: Recombinant Proteins Description: EBAG9 / RCAS1 (28-213, His-tag) human recombinant protein, 0.5 mg Species: Human Expression Host: E. coli Tag: His-tag Predicted MW: 23.4 kDa Concentration: lot specific Purity: >90% by SDS PAGE Buffer: Presentation State: Purified State: Liquid purified protein Buffer System: 20 mM Tris pH 8.0, 1 mM DTT, 2 mM EDTA, 10% glycerol Preparation: Liquid purified protein Protein Description: Recombinant human EBAG9 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography techniques. Note: (Real molecular weight on SDS-PAGE will be shift up). Storage: Store (in aliquots) at -20°C. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. RefSeq: NP_001265867 Locus ID: 9166 UniProt ID: O00559, A0A024R9E0 Cytogenetics: 8q23.2 Synonyms: EB9; PDAF This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 EBAG9 / RCAS1 (28-213, His-tag) Human Protein – AR09111PU-L Summary: This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene.
    [Show full text]
  • EBAG9 (NM 001278938) Human Untagged Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC334501 EBAG9 (NM_001278938) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: EBAG9 (NM_001278938) Human Untagged Clone Tag: Tag Free Symbol: EBAG9 Synonyms: EB9; PDAF Vector: pCMV6 series Fully Sequenced ORF: >NCBI ORF sequence for NM_001278938, the custom clone sequence may differ by one or more nucleotides ATGGCCATCACCCAGTTTCGGTTATTTAAATTTTGTACCTGCCTAGCAACAGTATTCTCATTCCTAAAGA GATTAATATGCAGATCTGGCAGAGGACGGAAATTAAGTGGAGACCAAATAACTTTGCCAACTACAGTTGA TTATTCATCAGTTCCTAAGCAGACAGATGTTGAAGAGTGGACTTCCTGGGATGAAGATGCACCCACCAGT GTAAAGATCGAAGGAGGGAATGGGAATGTGGCAACACAACAAAATTCTTTGGAACAACTGGAACCTGACT ATTTTAAGGACATGACACCAACTATTAGGAAAACTCAGAAAATTGTTATTAAGAAGAGAGAACCATTGAA TTTTGGCATCCCAGATGGGAGCACAGGTTTCTCTAGTAGATTAGCAGCTACACAAGATCTGCCTTTTATT CATCAGTCTTCTGAATTAGGTGACTTAGATACCTGGCAGGAAAATACCAATGCATGGGAAGAAGAAGAAG ATGCAGCCTGGCAAGCAGAAGAAGTTCTGAGACAGCAGAAACTAGCAGACAGAGAAAAGAGAGCAGCCGA ACAACAAAGGAAGAAAATGGAAAAGGAAGCACAACGGCTAATGAAGAAGGAACAAAACAAAATTGGTGTG AAACTTTCATAA Restriction Sites: SgfI-MluI ACCN: NM_001278938 OTI Disclaimer: Our molecular clone sequence data has been matched to the reference identifier above as a point of reference. Note that the complete sequence of our molecular clones may differ from the sequence published for this corresponding reference, e.g., by representing an alternative RNA splicing form
    [Show full text]
  • Differential Gene Regulation by the SRC Family of Coactivators
    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Differential gene regulation by the SRC family of coactivators Hua Zhang,1 Xia Yi,1 Xiaojing Sun, Na Yin, Bin Shi, Huijian Wu, Dan Wang, Ge Wu, and Yongfeng Shang2 Department of Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100083, China SRCs (steroid receptor coactivators) are required for nuclear receptor-mediated transcription and are also implicated in the transcription initiation by other transcription factors, such as STATs and NF␬B. Despite phenotypic manifestations in gene knockout mice for SRC-1, GRIP1, and AIB1 of the SRC (Steroid Receptor Coactivator) family indicating their differential roles in animal physiology, there is no clear evidence, at the molecular level, to support a functional specificity for these proteins. We demonstrated in this report that two species of SRC coactivators, either as AIB1:GRIP1 or as AIB1:SRC-1 are recruited, possibly through heterodimerization, on the promoter of genes that contain a classical hormone responsive element (HRE). In contrast, on non-HRE-containing gene promoters, on which steroid receptors bind indirectly, either GRIP1 or SRC-1 is recruited as a monomer, depending on the cellular abundance of the protein. Typically, non-HRE-containing genes are early genes activated by steroid receptors, whereas HRE-containing genes are activated later. Our results also showed that SRC proteins contribute to the temporal regulation of gene transcription. In addition, our experiments revealed a positive correlation between AIB1/c-myc overexpression in ER+ breast carcinoma samples, suggesting a possible mechanism for AIB1 in breast cancer carcinogenesis.
    [Show full text]
  • Primepcr™Assay Validation Report
    PrimePCR™Assay Validation Report Gene Information Gene Name Receptor-binding cancer antigen expressed on SiSo cells Gene Symbol Ebag9 Organism Rat Gene Summary Description Not Available Gene Aliases Not Available RefSeq Accession No. Not Available UniGene ID Rn.64132 Ensembl Gene ID ENSRNOG00000004220 Entrez Gene ID 299864 Assay Information Unique Assay ID qRnoCIP0027433 Assay Type Probe - Validation information is for the primer pair using SYBR® Green detection Detected Coding Transcript(s) ENSRNOT00000005705 Amplicon Context Sequence AGCAGCGCAGCAGAACTCTTTGGAACAACTGGAGCCTGACTATTTCAAGGACAT GACACCAACTATACGGAAAACGCAGAAAATTGTCATTAAGAAGAGAGAACCATTG AGTTTTGGTG Amplicon Length (bp) 89 Chromosome Location 7:83588185-83589886 Assay Design Intron-spanning Purification Desalted Validation Results Efficiency (%) 99 R2 0.9997 cDNA Cq 22.4295 cDNA Tm (Celsius) 78.5 gDNA Cq 32.635 Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report. Page 1/4 PrimePCR™Assay Validation Report Ebag9, Rat Amplification Plot Amplification of cDNA generated from 25 ng of universal reference RNA Melt Peak Melt curve analysis of above amplification Standard Curve Standard curve generated using 20 million copies of template diluted 10-fold to 20 copies Page 2/4 PrimePCR™Assay Validation Report Products used to generate validation data Real-Time PCR Instrument CFX384 Real-Time PCR Detection System Reverse Transcription Reagent iScript™ Advanced cDNA Synthesis Kit for RT-qPCR Real-Time PCR Supermix SsoAdvanced™ SYBR® Green Supermix Experimental Sample qPCR Reference Total RNA Data Interpretation Unique Assay ID This is a unique identifier that can be used to identify the assay in the literature and online. Detected Coding Transcript(s) This is a list of the Ensembl transcript ID(s) that this assay will detect.
    [Show full text]
  • EBAG9 (BC017729) Human Untagged Clone – SC122499 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for SC122499 EBAG9 (BC017729) Human Untagged Clone Product data: Product Type: Expression Plasmids Product Name: EBAG9 (BC017729) Human Untagged Clone Tag: Tag Free Symbol: EBAG9 Synonyms: cancer associated surface antigen; EB9; estrogen receptor binding site associated, antigen, 9; estrogen receptor binding site associated antigen 9; PDAF; RCAS1 Vector: pCMV6-XL5 E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: None Fully Sequenced ORF: >OriGene sequence for BC017729 edited CAGGCTGCTACGGAGCGCGCGCCCGGCTTTGAATGAGCGGGGCTGGGAGTGAGCGGGCGG AGCGCGAGCTCGAGGAAGAGACAGGCAGCGCGCGTGAGCGCGCCTTGTGTGCGCGCGCGG CCCGCGGCAGCTCGGAGCCTCCGCCGGGCGGGCGGGGAGGGGGAGGGGCAGGTTTTGATT CCCACCATGGCCATCACCCAGTTTCGGTTATTTAAATTTTGTACCTGCCTAGCAACAGTA TTCTCATTCCTAAAGAGATTAATATGCAGATCTGGCAGAGGACGGAAATTAAGTGGAGAC CAAATAACTTTGCCAACTACAGTTGATTATTCATCAGTTCCTAAGCAGACAGATGTTGAA GAGTGGACTTCCTGGGATGAAGATGCACCCACCAGTGTAAAGATCGAAGGAGGGAATGGG AATGTGGCAACACAACAAAATTCTTTGGAACAACTGGAACCTGACTATTTTAAGGACATG ACACCAACTATTAGGAAAACTCAGAAAATTGTTATTAAGAAGAGAGAACCATTGAATTTT GGCATCCCAGATGGGAGCACAGGTTTCTCTAGTAGATTAGCAGCTACACAAGATCTGCCT TTTATTCATCAGTCTTCTGAATTAGGTGACTTAGATACCTGGCAGGAAAATACCAATGCA TGGGAAGAAGAAGAAGATGCAGCCTGGCAAGCAGAAGAAGTTCTGAGACAGCAGAAACTA GCAGACAGAGAAAAGAGAGCAGCCGAACAACAAAGGAAGAAAATGGAAAAGGAAGCACAA CGGCTAATGAAGAAGGAACAAAACAAAATTGGTGTGAAACTTTCATAACACATGTTCAAA TTTTATCATGCCAGTAGGAGAAATCTCAGCTCCACAACCCAAGCAACATTTGTATGGATT
    [Show full text]
  • Role of EBAG9 in COPI-Dependent Glycoprotein Maturation and Secretion Processes in Tumor Cells
    Role of EBAG9 in COPI-Dependent Glycoprotein Maturation and Secretion Processes in Tumor Cells Dissertation zur Erlangung des akademischen Grades doctor rerum naturalium (Dr. rer. nat.) im Fach Biologie eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät I der Humboldt-Universität zu Berlin von Diplom-Biologin Jana Wolf, geb. Göttert Präsident der Humboldt-Universität zu Berlin Prof. Dr. Dr. h.c. Christoph Markschies Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I Prof. Dr. Andreas Herrmann Gutachter/innen: 1. Prof. Dr. Thomas Börner 2. Prof. Dr. med. Bernd Dörken 3. PD Dr. Uta Höpken Tag der mündlichen Prüfung: 21.10.2010 Index of contents Index of contents ABSTRACT......................................................................................................................................................... VI ZUSAMMENFASSUNG....................................................................................................................................VII 1 INTRODUCTION......................................................................................................................................... 1 1.1 THE TUMOR ASSOCIATED ANTIGEN EBAG9 ............................................................................................. 1 1.1.1 Features of EBAG9 protein............................................................................................................. 1 1.1.2 EBAG9 and cancer.........................................................................................................................
    [Show full text]
  • Immunological and Translational Consequences of an Altered CD8+ T Cell Cytolytic Activity
    Immunological and translational consequences of an + altered CD8 T cell cytolytic activity Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Anthea Wirges 2018 Die vorliegende Arbeit wurde in der Zeit vom Juli 2014 bis Dezember 2018 in der Arbeitsgruppe „Translationale Tumorimmunologie“ unter der Leitung von Dr. Armin Rehm am „Max-Delbrück-Centrum für Molekulare Medizin“ in der Helmholtz- Gemeinschaft in Berlin angefertigt. 1. Gutachter: Dr. Armin Rehm 2. Gutachter: Prof. Dr. Oliver Daumke Disputation: 06.05.2019 4 Index I ABBREVATIONS ..................................................................................................... V II TABLES .................................................................................................................. XI III FIGURES .............................................................................................................. XIII IV ZUSAMMENFASSUNG ............................................................................................ 1 V ABSTRACT ............................................................................................................... 3 1. INTRODUCTION ....................................................................................................... 5 1.1 The immune system .......................................................................................... 5 1.2 T cell-mediated immunity ..................................................................................
    [Show full text]
  • Rabbit Anti-RCAS1/EBAG9/FITC Conjugated Antibody
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-RCAS1/EBAG9/FITC Conjugated antibody SL10982R-FITC Product Name: Anti-RCAS1/EBAG9/FITC Chinese Name: FITC标记的Tumour相关表面抗原EBAG9抗体 BAG9; Cancer associated surface antigen; Cancer associated surface antigen RCAS1; EB9; EBAG 9; Estrogen receptor binding fragment associated gene 9 protein; Estrogen Alias: receptor binding site associated antigen 9; PDAF; RCAS 1; RCAS1; Receptor binding cancer antigen expressed on SiSo cells. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Chicken,Pig,Cow,Rabbit, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 24kDa Form: Lyophilized or Liquid Concentration: 2mg/1ml immunogen: KLHwww.sunlongbiotech.com conjugated synthetic peptide derived from human RCAS1 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: This gene was identified as an estrogen-responsive gene. Regulation of transcription by Product Detail: estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene.
    [Show full text]